Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
Deanna Kerrigan(Milken Institute), Miranda Murray(ViiV Healthcare (United Kingdom)), Andrea Mantsios(Action Network), Marisa Montes(Hospital La Paz Institute for Health Research), Gary Richmond(University of Fort Lauderdale), Jerome Devente(Hope Foundation), Cynthia Brinson, Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Paige Hammond(Johns Hopkins University), Federico Pulido(Bellvitge University Hospital), S. Wilson Beckham(Johns Hopkins University), David M. Margolis(University of North Carolina at Chapel Hill)
Cited by 179
Related Papers
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
The Challenge of Finding a Cure for HIV Infection
|Science|2009|850
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
|The Lancet HIV|2020|177
Severe Dengue Virus Infection in Travelers: Risk Factors and Laboratory Indicators
|The Journal of Infectious Diseases|2007|173